NVST
Envista Holdings CorpPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 10 ▼ 1 insider sell $290.3K at $30.00
- Jul 9 BMO Capital initiates
- Aug 20 ▼ 1 insider sell $220.0K at $27.50
- Sep 3 ▲ JP Morgan upgrades
- Oct 15 ▼ Baird downgrades
- Nov 4 ▲ Envista reported Q3 2026 adjusted EPS of $0.40, beating the $0.36 co…
- Nov 4 ▲ Earnings: NVST Q3 2026 Earnings: EPS $0.4 (+10.0% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $510.3K.
- InstitutionsBULLISH
Q3 2026: 50 added (2 new), 14 trimmed or exited. Largest new: Qube Research & Technologies $40.6M.
- AnalystsBULLISH
12 of 22 rate it Buy or better. Median target $29.00 (+21%).
- Short sellersSTEADY
Short interest −0.5% to 9.73M shares. 3.0 days to cover, ≈6.1% of shares.
- TrendRANGE
0% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $158.1M |
| AMERICAN CENTURY COMPANIES INC | ADD | $124.5M |
| UBS Group AG | ADD | $67.8M |
| FRANKLIN TEMPLETON INC | TRIM | $67.5M |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | $57.2M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | $47.7M |
| Qube Research & Technologies Ltd | NEW | $40.6M |
| FMR LLC | ADD | $39.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
22 analystsPrice is inside the target range. Median implies +21%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | UBS MAINTAIN | Neutral |
| Nov 5, 2026 | Evercore ISI Group MAINTAIN | Outperform |
| Oct 15, 2026 | Baird DOWNGRADE | Neutral |
| Oct 14, 2026 | Leerink Partners MAINTAIN | Outperform |
| Oct 9, 2026 | Piper Sandler MAINTAIN | Neutral |
| Sep 28, 2026 | BMO Capital MAINTAIN | Market Perform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Keel Paul A Chairman and CEO Nov 1, 2026 | TAX W/H | $1.3M |
Hammes Eric D. Chief Financial Officer Aug 25, 2026 | TAX W/H | $299.0K |
Nilsson Stefan President, Nobel Biocare Aug 25, 2026 | TAX W/H | $22.1K |
Befidi Robert President, Diagnostics Aug 25, 2026 | TAX W/H | $141.4K |
Acurio Veronica President, Orthodontics Aug 25, 2026 | TAX W/H | $211.8K |
Reis Mischa SVP, Strategy & Bus. Dev. Aug 20, 2026 | SELL | $220.0K |
Keel Paul A Chief Executive Officer Aug 18, 2026 | AWARD | 159,900 sh |
Hammes Eric D. Chief Financial Officer Aug 18, 2026 | AWARD | 47,970 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 2 bullish · 0 bearish · 1 mixed · 8 neutral- NEUTRAL SC 13GNov 13, 2026
AQR Capital Management disclosed a 5.29% passive stake in Envista Holdings Corp as of September…
AQR's new 5.29% passive stake adds a notable institutional holder but carries no activist intent. Monitor future 13F filings for position changes and any subsequent 13D conversion if AQR engages…
- NEUTRAL INST-CLUSTERNov 9, 2026
Ten institutional investors accumulated $12.2M in net new NVST positions during Q3 2026, while two…
The cluster is dominated by small-to-mid-sized asset managers doubling or adding positions, but the absence of activist or high-conviction hedge funds and the lack of insider buying weaken the…
- NEUTRAL S-3ASRNov 9, 2026
Envista filed an automatic shelf registration statement (S-3ASR) to register an indeterminate…
Monitor for a prospectus supplement that would disclose actual offering size, pricing and use of proceeds. The timing after a strong earnings report suggests the company may be positioning for…
- BULLISH 8-KNov 4, 2026
Envista reported Q3 2026 adjusted EPS of $0.40, beating the $0.36 consensus by 11.1%, on revenue…
The raised guidance and continued margin expansion signal operational momentum. Monitor the Q4 earnings call for sustainability of core sales growth and any impact from macro headwinds on dental…
All NVST filing & press-release reports (11)
- SC 13G reportNov 13, 2026
- INST-CLUSTER reportNov 9, 2026
- S-3ASR reportNov 9, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- INST-CLUSTER reportOct 27, 2026
- 8-K reportOct 27, 2026
- 8-K reportSep 17, 2026
- 8-K reportAug 19, 2026
- 8-K reportJun 3, 2026
- DEFA14A reportApr 7, 2026